- Home
- KFS vs RIGL Comparison
KFS vs RIGL Comparison
Compare KFS & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KFS
- RIGL
- Stock Information
- Founded
- KFS 1989
- RIGL 1996
- Country
- KFS United States
- RIGL United States
- Employees
- KFS N/A
- RIGL N/A
- Industry
- KFS Property-Casualty Insurers
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- KFS Finance
- RIGL Health Care
- Exchange
- KFS Nasdaq
- RIGL Nasdaq
- Market Cap
- KFS 417.8M
- RIGL 335.5M
- IPO Year
- KFS 1996
- RIGL 2000
- Fundamental
- Price
- KFS $14.37
- RIGL $38.85
- Analyst Decision
- KFS
- RIGL Buy
- Analyst Count
- KFS 0
- RIGL 5
- Target Price
- KFS N/A
- RIGL $38.20
- AVG Volume (30 Days)
- KFS 69.0K
- RIGL 995.6K
- Earning Date
- KFS 08-07-2025
- RIGL 08-05-2025
- Dividend Yield
- KFS N/A
- RIGL N/A
- EPS Growth
- KFS N/A
- RIGL N/A
- EPS
- KFS N/A
- RIGL 5.43
- Revenue
- KFS $119,287,000.00
- RIGL $267,921,000.00
- Revenue This Year
- KFS N/A
- RIGL $59.93
- Revenue Next Year
- KFS N/A
- RIGL N/A
- P/E Ratio
- KFS N/A
- RIGL $7.15
- Revenue Growth
- KFS 12.05
- RIGL 105.62
- 52 Week Low
- KFS $7.06
- RIGL $12.66
- 52 Week High
- KFS $16.80
- RIGL $43.72
- Technical
- Relative Strength Index (RSI)
- KFS 54.71
- RIGL 68.57
- Support Level
- KFS $13.96
- RIGL $39.00
- Resistance Level
- KFS $14.36
- RIGL $42.08
- Average True Range (ATR)
- KFS 0.38
- RIGL 2.32
- MACD
- KFS 0.05
- RIGL -0.37
- Stochastic Oscillator
- KFS 89.60
- RIGL 53.26
About KFS Kingsway Financial Services Inc. (DE)
Kingsway Financial Services Inc through subsidiaries operates in the extended warranty and business services industries in the United States. The company operates through segments namely, Extended Warranty and Kingsway Search Xcelerator. The Extended Warranty segment provides after-market vehicle protection services distributed by credit unions. The firm generates maximum revenue from the Extended Warranty segment in the form of Service fee and commission income.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.